Introduction
NiemannePick disease type C (NPC, OMIM 257220) is a rare lysosomal storage disease characterized by a defect in lipid trafficking within organelles. This is primarily due to the impaired functions of the NPC1 or NCP2 proteins. Several types of lipids including unesterified free cholesterol, sphingosine, sphingomyelin, phospholipids and glycosphingolipids accumulate in the lysosomes and late endosomes, 1 resulting in organomegaly, impaired liver function and progressive neurological damage. Neurological symptoms may include psychomotor retardation, clumsiness, ataxia, dysphagia, dysarthria, presenile dementia and vertical supranuclear gaze palsy. Psychiatric manifestations are often reported in adolescent and adult patients. 2 In general, the age of onset of neurological signs inversely correlates with progression rates.
In the juvenile and adult onset forms, psychomotor development is usually normal in the early ages, but a gradual loss of previously acquired skills may suggest the underlying neurometabolic disease. It seems that visceral symptoms decrease and neuropsychiatric symptoms emerge with advancing age. 3 There is no curative therapy for NPC e slowing disease progression is the most promising option. In 2009, miglustat (Zavesca, Actelion Pharmaceuticals, Allschwil, Switzerland) was approved by European Union countries as the only specific therapy of the disease. The mechanism of action includes the inhibition of glycosphingolipid synthesis, thus reducing the accumulation of storage material in NPC1 deficient cells, resulting in partial improvement or stabilization of neurological symptoms. The latest guidelines recommend the initiation of miglustat following the appearance of neurological symptoms. 4 However, the extreme heterogeneity of the disease, the subtle clinical symptoms may hinder its recognition and severely delay the initiation of adequate therapy. Several cases presenting with psychosis and schizophrenia-like symptoms remain undetected. 5 In this paper, the authors present a case of a young adult patient with juvenile onset NPC who suffered from a severe psychotic episode but fully recovered following miglustat therapy.
Case study
Patient (male) was born from unrelated, healthy Caucasian parents. The perinatal and infantile period was uneventful. No prolonged neonatal jaundice was noted. Psychomotor development was normal until adolescence, although attention deficit and delayed reactions to environmental stimuli was reported since preschool age. Involuntary torsion-like movements of the arms were first noted at 10 years of age but were misjudged as a bad habit or tick. At age 14, a consultation with a paediatric neurologist took place due to symptoms such as slurred speech and coordination problems. The parents reported frequent falls and loss of balance. On physical examination, slight swaying to the right in Romberg's test and right deviation of the tongue was described. Audiological examination revealed central hypacusis at high frequencies. Brain MRI was normal. Later, dyslexia and dysgraphia developed, but the patient fulfilled the normal curriculum with satisfactory grades until he was 17 years old. A paediatric psychologist estimated his intellect to be normal, with verbal performance in the average range and motor performance slightly below average. Fine motor skills started to decline more rapidly at age 17, and dysphagia developed. A repeated neurological examination disclosed mild central facial paresis, diminished pharyngeal reflexes, dysarthria, subjective dysphagia, mild cerebellar ataxia, dystonia of the hands and fingers and vertical supranuclear gaze palsy when looking downwards. The possibility of a neurodegenerative disease was raised, but a repeated MRI showed no abnormality (Fig. 1A) . However, brain-stem auditory evoked potentials signalled diffuse brain stem dysfunction. Abdominal ultrasonography showed isolated splenomegaly, the estimated volume of the spleen was 440 mL, which, together with the vertical supranuclear gaze palsy and the gradual decline of motor skills suggested NiemannePick C disease. A bone marrow biopsy was performed and confirmed the presence of CD68 positive foamy macrophages, also staining positive with Oil Red O. Fibroblast filipin staining was performed at the Mayo Clinic, Rochester, MN, USA according to standard protocol but it could not confirm and neither rule out NPC, cholesterol esterification rate was 17% of the normal control but higher than in control NPCdeficient fibroblasts. For mutation analysis, NPC1 exons were individually amplified and sequenced. Compound heterozygous missense mutations in the NPC1 gene were found: c.3019 C > G mutation in exon 20 (p. Pro1007Ala), and c.3182 T > C in exon 21 (p. Ile1061Thr) resulting in the genotype of [c.3019 1D ). Both mutations were described previously in the literature, their pathogenicity is proven. 6, 7 Testing of the parents' sample revealed that the c.3019 C > G mutation was inherited from the mother while the c.3182 T > C mutation from the father. At age 20.5 years remarkable cognitive and behavioural changes occurred: visual hallucinations, paranoid thoughts and distortion of the reality caused the parents to seek medical help for their child. He lost his ability of spatial orientation and reacted inadequately in everyday situations. Attention span was reduced. MMSE was 30/23 suggesting dementia and cognitive decline. Over the next four weeks, persecutory delusions, sleep disturbance, anxiety, bizarre paranoid doxasmas developed, for which psychiatric inpatient care was needed. Olanzapine 10 mg/die and clonazepam 2 mg/die (0.5e0.5e1 mg) were introduced. Brain MRI at this time showed moderate degree diffuse cerebral atrophy (Fig. 1B) . IQ could not be measured because of incoherent thinking. After two weeks of ineffectiveness, the dose of olanzapine was increased to 20 mg/die, the maximum adult dose, and that of clonazepam was reduced to 0.5 mg/die. Seeing no improvement of symptoms after another two weeks of modified therapy, both drugs were gradually omitted and first-generation haloperidol 3 Â 1.5 mg was introduced. This resulted in little partial improvement, but with respect to his best achievable status, the patient was emitted from hospital (10 weeks from the onset of psychotic symptoms). Haloperidol was maintained in a dose of 2 Â 0.75 mg/die. However, only 5 weeks later a dystonic crisis appeared, and haloperidol had to me omitted. We tried aripiprazole (15 mg/die), another firstgeneration antipsychotic known to provoke fewer extrapyramidal side effects, yet the movement disorder was so severe that aripiprazole could not be continued. The dystonic storm was successfully treated with intravenous diazepam and biperiden, carbamazepine suppository and oral baclofen. Right after the approval of the drug in Hungary (six weeks from the onset of psychotic symptoms), miglustat was introduced in a dose of 3 Â 200 mg per day, and was given strictly throughout the course of the psychotic disease independent from other medications. Its side effect was temporary diarrhoea resolving spontaneously after six months of therapy. Three months after the initiation of miglustat and two weeks
after cessation of all antipsychotics from necessity in a nonsymptom-free psychiatric status, psychotic symptoms gradually resolved and did not recur ever since. Brain MRI performed at age 22 and also at 23 years showed no progression of cerebral atrophy (Fig. 1C) . At age 23 years, after 3 years of follow-up, the patient had an overall IQ of 79, certain skills were more severely affected than others: verbal intelligence was in average range (VQ ¼ 92), performance intelligence reflected mild mental subnormality (PQ ¼ 68). MMSE is 30/26. He recognized social and moral norms above average level, logical thinking, reasoning, mathematical skills and visuomotor coordination were severely impaired. At present, aged 24 years, the above mentioned fairly good psychomotor status is still preserved. The patient requires round the clock supervision by his parents but remained ambulatory, capable of self-care and does sports on an everyday basis. No signs of psychosis have reappeared in the past 3 years.
Discussion
Neuropsychiatric manifestations of NiemannePick C disease may occur at any stage of the disease and are most likely to define clinical outcome over other symptoms. Apart from early dementia and cognitive decline, schizophrenia, depression or psychosis are often reported, especially in adolescent and adult patients. 2 Recently, an NPC suspicion index was developed to help professionals enhance the early recognition of the disease. 8 Reducing time interval between the onset of symptoms and the definitive diagnosis appears to be of paramount importance. Emerging treatments should be more efficient at the visceral or cognitive/psychiatric stages of the disease, before the occurrence of widespread deep brain neurological lesions. 9, 10 In 2009, miglustat was approved as the only specific therapy of NPC and was found to achieve stabilization or partial improvement of neurological symptoms. According to the recommendations of the NPC Guidelines Working Group, patients without neurological manifestations should not receive miglustat as some can remain asymptomatic for a considerable period of time. In cases where severe neurological impairment is already present at the time of diagnosis, particularly in very young patients, miglustat is less likely to provide substantial therapeutic benefits. 11 To date, a number of clinical research focus on the beneficial therapeutic effect of miglustat upon the neurological manifestations of the disease, but only a few deal with its favourable influence upon psychiatric symptoms, social behaviour and quality of life from the patients' and caregivers' perspectives. 5 Here we presented a case of a patient with juvenile-onset NPC who suffered from a severe psychotic episode that resisted to all administered antipsychotic medications but was ameliorated by miglustat within three months, and a fairly good quality of life was regained. Our conviction that miglustat is responsible for such a favourable change in the mental status of the patient is supported by the observations that 1) no significant improvement could be achieved with antipsychotic medications, 2) improvement occurred when no conventional antipsychotics could be given due to severe dystonia and miglustat was the only medication the patient received apart from oral anticholinergic pyridostigmin as long as the dystonic crisis lasted, and 3) psychotic symptoms have not recurred in 3 years of follow up. We also aim to point out that vertical supranuclear gaze palsy, isolated splenomegaly, bulbar signs and gradual psychomotor decline of a previously symptom-free young patient were key features suggesting NiemannePick C disease, thus providing a basis for clinical and molecular diagnosis. In patients where psychiatric symptoms occur earlier than the knowledge of the underlying metabolic disease is gained, there is a greater chance that physicians focus on treating the mental illness and miss important signal signs that could indicate its organic origin and direct health care professionals to initiate a specific e although not curative e therapy. Based on our clinical experience we suggest a careful revision of the anamnesis and checking for vertical supranuclear gaze palsy and bulbar symptoms such as difficulties in swallowing and articulation in all patients with schizophrenia and psychosis, and encourage the introduction of miglustat in NPC patients even in a more advanced stage of psychiatric illness.
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